Derek Burns, PharmD, MBA, BCPS, BCSCP

By decade’s end, approval of additional bispecifics is expected for hematological malignancies, solid tumors, and non-oncology conditions such as inflammatory, autoimmune, neurodegenerative and vascular diseases, and ocular disorders and infections.

Successfully integrating biosimilars into practices requires careful planning and execution, as they impact virtually all aspects of a practice.

While waiting for budgetary approvals, there are some simple initiatives outpatient oncology practices can initiate that yield high rewards and quick wins yet cost little more than an investment of time.

Compliance is achievable for outpatient oncology practices with careful planning and execution.